A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of advanced and/or metastatic solid tumor or lymphoma that is refractory to standard therapy * Measurable or evaluable disease * Score of 0 to 2 on the ECOG performance scale Exclusion Criteria: * Concurrent serious medical illness * Known, clinically suspected, or history of central nervous system (CNS) tumor involvement * Active diarrhea * Known history of coagulation disorder * Patients requiring cytochrome P450 3A4 (CYP3A4) enzyme inducing medications * Requirement for ketoconazole or other strong inhibitor of CYP3A4 enzymes * Prior chemotherapy, immunotherapy, investigational agent, or other therapy used to treat the cancer within 4 weeks (6 weeks for prior treatment with mitomycin C or nitrosoureas) prior to the scheduled administration of EZN-2208.